Cooley advised Zymergen on patent prosecution and IP diligence matters surrounding its $400 million Series C funding which closed in December 2018 and was led by returning investor SoftBank Vision Fund. The deal is the largest round of funding for a US-based startup operating upstream in the food and agriculture supply chain. Cooley lawyers Erich Veitenheimer and Chris Holly headed the team advising Zymergen.
Zymergen is the world’s first molecular manufacturing technology company, developing molecules used in industries including agriculture, chemicals, materials, pharmaceuticals, electronics and more.
Cooley’s patent team advises Zymergen on all aspects of IP matters, including the company’s foundational high-throughput genomic engineering platform.